Literature DB >> 22244007

Plasma-derived medicines: access and usage issues.

Albert Farrugia1, Josephine Cassar.   

Abstract

Mesh：

Year:  2012        PMID： 22244007      PMCID： PMC3417725          DOI： 10.2450/2011.0118-11

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  35 in total

Review 1.  Falsificationism and clinical trials.

Authors:  S J Senn
Journal:  Stat Med       Date:  1991-11       Impact factor: 2.373

Review 2.  Subcutaneous administration of IgG.

Authors:  Melvin Berger
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

3.  Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.

Authors:  Mary Lucas; Martin Lee; Jenny Lortan; Eduardo Lopez-Granados; Siraj Misbah; Helen Chapel
Journal:  J Allergy Clin Immunol       Date:  2010-05-14       Impact factor: 10.793

4.  Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.

Authors:  A M Cheraghali; R Aboofazeli
Journal:  Transfus Med       Date:  2009-09-23       Impact factor: 2.019

5.  Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia.

Authors:  G C White; C W McMillan; H S Kingdon; C B Shoemaker
Journal:  N Engl J Med       Date:  1989-01-19       Impact factor: 91.245

6.  Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.

Authors:  J G Pool; A E Shannon
Journal:  N Engl J Med       Date:  1965-12-30       Impact factor: 91.245

7.  The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.

Authors:  H W Eijkhout; J W van Der Meer; C G Kallenberg; R S Weening; J T van Dissel; L A Sanders; P F Strengers; H Nienhuis; P T Schellekens
Journal:  Ann Intern Med       Date:  2001-08-07       Impact factor: 25.391

Review 8.  Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.

Authors:  C Escuriola Ettingshausen; W Kreuz
Journal:  Haemophilia       Date:  2006-12       Impact factor: 4.287

9.  Elective fresh frozen plasma in the critically ill: what is the evidence?

Authors:  Santosh G Verghese
Journal:  Crit Care Resusc       Date:  2008-09       Impact factor: 2.159

10.  Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand.

Authors:  J S Stonebraker; R E Amand; M V Bauman; A J Nagle; P J Larson
Journal:  Haemophilia       Date:  2004-01       Impact factor: 4.287
View more
  4 in total

Review 1.  Is self-sufficiency in haemotherapies a practical or necessary goal?

Authors:  Albert Farrugia; Josephine Cassar
Journal:  Blood Transfus       Date:  2012-12-13       Impact factor: 3.443

2.  Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin.

Authors:  Jeffrey S Stonebraker; Albert Farrugia; Benjamin Gathmann; Jordan S Orange
Journal:  J Clin Immunol       Date:  2013-12-12       Impact factor: 8.317

Review 3.  Implementation of Plasma Fractionation in Biological Medicines Production.

Authors:  Kamran Mousavi Hosseini; Mehran Ghasemzadeh
Journal:  Iran J Biotechnol       Date:  2016-12       Impact factor: 1.671

4.  Cost effectiveness of Iran national plasma contract fractionation program.

Authors:  Abdol Majid Cheraghali
Journal:  Daru       Date:  2012-10-22       Impact factor: 3.117
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.